Satsuma Pharmaceuticals has presented phase 1 data on its second-generation nasal delivery device. The readout positions Satsuma to start a phase 3 clinical trial designed to enable it to bounce back ...
Not all defects are visible with the same microscope. Explore how resolution, contrast, and signal interpretation shape ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results